Recently proposed data on the ibuprofen API market analysis demonstrates that demand for ibuprofen APIs is valued at around US$ 665 million in 2024 and is on its way to register a CAGR of 2.5% to reach US$ 851 million by 2034. The evolving landscape in emerging economies propels the demand boost in the API sector, shaping the pharmaceutical metamorphosis.
Attributes | Details |
---|---|
Market Value for 2024 | US$ 665 million |
Market Value for 2034 | US$ 851 million |
Market Forecast CAGR for 2024 to 2034 | 2.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Demand is presumed to limit the market growth. The historical CAGR of 3.0% was recorded for the market and a 2.5% CAGR is calculated through 2034.
Attributes | Details |
---|---|
Market Historical CAGR for 2019 to 2023 | 3.0% |
The synthesis of ibuprofen APIs has environmental drawbacks due to revised production guidelines, affecting manufacturers' costs and raw material sourcing. This has led to a downturn in the market, as the drug requires high production value.
Key aspects to influence the demand through 2034 include:
Market players need to be prudent and flexible over the anticipated period, as these challenging attributes position the industry for success in the subsequent decade.
Female Patients Creates a Huge Demand
The Pharmaceutical and Biochemical Industry Rife Ibuprofen Depletion
Demand for Arthritis Medication Rumbles the Growth Rate
Attributes | Details |
---|---|
Top End User | Contract Manufacturing Organization |
Market share in 2024 | 55.30% |
Demand from contract manufacturing organizations (CMOs) is significant, acquiring a market share of 55.6% in 2024. The following aspects contribute to the development of demand from contract manufacturing organizations:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
According to derived data, demand from European countries to augment the sales growth in the forthcoming decade. The industry in France and Germany is developing steeply. The ibuprofen drug substance industry in Canada to register the subordinate CAGR compared to European competitors. Demand in Italy and Spain to remain moderate throughout.
Countries | CAGR from 2024 to 2034 |
---|---|
Spain | 3.7% |
Germany | 2.7% |
Italy | 3.3% |
Canada | 2.0% |
France | 3.0% |
Through 2034, the industry in Spain is anticipated to register a 3.7% CAGR, owing to the development of prominent and emerging pharmaceutical and biopharma organizations.
Demand is projected to report a CAGR of 2.7% in Germany through 2034, due to the rising prevalence of chronic diseases such as arthritis and osteoporosis.
Demand in Italy is anticipated to showcase a CAGR of 3.3% between 2024 and 2034 as geriatric patients grow nationwide.
Demand in France is projected to report a CAGR of 3.0% from 2024 to 2034, as women desire demand for ibuprofen API to ease menstruation pain.
Sales is developing rapidly in Canada, witnessing a CAGR of 2.0% through 2034, owing to regular climate change in Canada.
Ibuprofen pharmaceutical ingredient suppliers are merging with CMOs to enhance raw material supply and streamline manufacturing processes, resulting in cost savings and improved time efficiency.
The pharmaceutical API sector is experiencing a surge in mergers and acquisitions, driven by companies seeking therapeutic, pipeline, and global expansion goals. These strategies are gaining popularity due to their significant benefits.
Pooling resources allows companies to create economies of scale, reduce costs, and increase efficiency, especially in product development. Mergers and acquisitions extend market share and help reach new customers for long-term growth.
Mergers and acquisitions are a key growth strategy in the industry, enabling companies to maintain competitiveness, expand globally, and enhance their raw material supply.
Recent Developments in the Ibuprofen API Market
The market is valued at US$ 665 million in 2024.
The market is anticipated to be valued at US$ 861.3 million by 2034.
In Canada, demand is anticipated to develop at a CAGR of 2.0% through 2034.
The market is projected to register a CAGR of 2.50% from 2024 to 2034.
The contract manufacturing organizations develops demand for ibuprofen APIs with a 55.3% market share in 2024.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Prescription Based 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Prescription Based, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Prescription Based, 2024 to 2034 5.3.1. Rx 5.3.2. OTC 5.4. Y-o-Y Growth Trend Analysis By Prescription Based, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Prescription Based, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034 6.3.1. Headache 6.3.2. Arthritis 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2024 to 2034 7.3.1. Contract Research Organization 7.3.2. Contract Manufacturing Organization 7.3.3. Biopharmaceutical Companies 7.3.4. Pharmaceutical Companies 7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Prescription Based 9.2.3. By Application 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Prescription Based 9.3.3. By Application 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Prescription Based 10.2.3. By Application 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Prescription Based 10.3.3. By Application 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Prescription Based 11.2.3. By Application 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Prescription Based 11.3.3. By Application 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Prescription Based 12.2.3. By Application 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Prescription Based 12.3.3. By Application 12.3.4. By End User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Prescription Based 13.2.3. By Application 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Prescription Based 13.3.3. By Application 13.3.4. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Prescription Based 14.2.3. By Application 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Prescription Based 14.3.3. By Application 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Prescription Based 15.2.3. By Application 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Prescription Based 15.3.3. By Application 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Market Share Analysis, 2023 16.1.1.1. By Prescription Based 16.1.1.2. By Application 16.1.1.3. By End User 16.2. Canada 16.2.1. Market Share Analysis, 2023 16.2.1.1. By Prescription Based 16.2.1.2. By Application 16.2.1.3. By End User 16.3. Brazil 16.3.1. Market Share Analysis, 2023 16.3.1.1. By Prescription Based 16.3.1.2. By Application 16.3.1.3. By End User 16.4. Mexico 16.4.1. Market Share Analysis, 2023 16.4.1.1. By Prescription Based 16.4.1.2. By Application 16.4.1.3. By End User 16.5. Germany 16.5.1. Market Share Analysis, 2023 16.5.1.1. By Prescription Based 16.5.1.2. By Application 16.5.1.3. By End User 16.6. UK 16.6.1. Market Share Analysis, 2023 16.6.1.1. By Prescription Based 16.6.1.2. By Application 16.6.1.3. By End User 16.7. France 16.7.1. Market Share Analysis, 2023 16.7.1.1. By Prescription Based 16.7.1.2. By Application 16.7.1.3. By End User 16.8. Spain 16.8.1. Market Share Analysis, 2023 16.8.1.1. By Prescription Based 16.8.1.2. By Application 16.8.1.3. By End User 16.9. Italy 16.9.1. Market Share Analysis, 2023 16.9.1.1. By Prescription Based 16.9.1.2. By Application 16.9.1.3. By End User 16.10. Poland 16.10.1. Market Share Analysis, 2023 16.10.1.1. By Prescription Based 16.10.1.2. By Application 16.10.1.3. By End User 16.11. Russia 16.11.1. Market Share Analysis, 2023 16.11.1.1. By Prescription Based 16.11.1.2. By Application 16.11.1.3. By End User 16.12. Czech Republic 16.12.1. Market Share Analysis, 2023 16.12.1.1. By Prescription Based 16.12.1.2. By Application 16.12.1.3. By End User 16.13. Romania 16.13.1. Market Share Analysis, 2023 16.13.1.1. By Prescription Based 16.13.1.2. By Application 16.13.1.3. By End User 16.14. India 16.14.1. Market Share Analysis, 2023 16.14.1.1. By Prescription Based 16.14.1.2. By Application 16.14.1.3. By End User 16.15. Bangladesh 16.15.1. Market Share Analysis, 2023 16.15.1.1. By Prescription Based 16.15.1.2. By Application 16.15.1.3. By End User 16.16. Australia 16.16.1. Market Share Analysis, 2023 16.16.1.1. By Prescription Based 16.16.1.2. By Application 16.16.1.3. By End User 16.17. New Zealand 16.17.1. Market Share Analysis, 2023 16.17.1.1. By Prescription Based 16.17.1.2. By Application 16.17.1.3. By End User 16.18. China 16.18.1. Market Share Analysis, 2023 16.18.1.1. By Prescription Based 16.18.1.2. By Application 16.18.1.3. By End User 16.19. Japan 16.19.1. Market Share Analysis, 2023 16.19.1.1. By Prescription Based 16.19.1.2. By Application 16.19.1.3. By End User 16.20. South Korea 16.20.1. Market Share Analysis, 2023 16.20.1.1. By Prescription Based 16.20.1.2. By Application 16.20.1.3. By End User 16.21. GCC Countries 16.21.1. Market Share Analysis, 2023 16.21.1.1. By Prescription Based 16.21.1.2. By Application 16.21.1.3. By End User 16.22. South Africa 16.22.1. Market Share Analysis, 2023 16.22.1.1. By Prescription Based 16.22.1.2. By Application 16.22.1.3. By End User 16.23. Israel 16.23.1. Market Share Analysis, 2023 16.23.1.1. By Prescription Based 16.23.1.2. By Application 16.23.1.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Prescription Based 17.3.3. By Application 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. BASF SE 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. BIOCAUSE Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. IOL Chemicals And Pharmaceuticals Limited 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. SI Group, Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Solara Active Pharma Sciences Limited 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Granules India Limited 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Dr. Reddy's Laboratories Ltd 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Octavius Pharma Pvt. Ltd 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Rochem International Inc 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
June 2023
REP-GB-13025
273 pages
Explore Healthcare Insights
View Reports